Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations
© Tukaj et al.; licensee BioMed Central Ltd. 2014
Received: 21 November 2013
Accepted: 24 March 2014
Published: 2 April 2014
Heat shock protein 90 (Hsp90), a chaperone that regulates activity of many client proteins responsible for cellular growth, differentiation, and apoptosis, has been proposed as an important clinical and preclinical therapeutic target in a number of malignancies and autoimmune diseases, respectively. In this study, we evaluated the effects of pharmacological Hsp90 inhibition on human proinflammatory T cell responses.
Using anti-CD3 antibody-stimulated human peripheral blood mononuclear cell cultures, we observed that Hsp90 inhibition by non-toxic concentrations of the geldanamycin derivative 17-DMAG significantly blocked T cell proliferation, reduced IFN-γ and IL-17 expression on CD4+ T lymphocytes, and arrested secretion of proinflammatory IFN-γ, TNF-α, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively. These effects were associated with inhibition of NF-kB activity, upregulation of Hsp70 protein expression, and disruption of T cell-specific nonreceptor tyrosine kinase Lck activation.
Our results further support the potential use of Hsp90 inhibitors in patients with autoimmune diseases where uncontrolled Th1 or Th17 activation frequently occurs.
Keywords17-DMAG Heat shock protein T cell
Heat shock protein 90 (Hsp90) is an ATP-dependent molecular chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-associated kinases and transcription factors, but has been also shown to exert potent immunomodulatory actions[1, 2].
Several pieces of evidence show that Th1 and Th17 cells are pathophysiologically associated with several autoimmune diseases and that Hsp90 activity is required for IFN-γ and IL-17 signaling in these cell types, respectively[3–5]. Based on these findings and the observations that Hsp90 plays important roles in antigen presentation, activation of lymphocytes, macrophages, and dendritic cells, we and others claim that pharmacological inhibition of Hsp90 is a promising therapy to ameliorate inflammatory cascades in autoimmune diseases[6–11].
In the present study, we show that blockade of Hsp90 by the geldanamycin derivative 17-DMAG leads to inhibition of T cell proliferation, suppression of IFN-γ and IL-17 expression on CD4+ T cells, and attenuation of secretion of proinflammatory IFN-γ, TNF-α, and IL-17, cytokines characteristic of Th1 and Th17 cells, respectively.
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of 11 healthy volunteers (age 25-35 years, mean 29.72 ± 3.47, 6 females and 5 males) by Ficoll-Paque (GE Healthcare Bio-Sciences) gradient centrifugation and cultured as described previously with minor modification. Briefly, PBMCs were washed twice in PBS and resuspended at 0.5 × 105 or 1 × 106 cells per ml of medium (RPMI 1640 supplemented with 10% fetal calf serum, 2 mM L-glutamine, and penicillin/streptomycin). Cells were cultured in the presence of 1 μg/ml immobilized anti-CD3 mAb (BD Bioscience) in 24-well or 96-well culture plates in 5% CO2 at 37°C without or with different concentration of 17-DMAG (InVitrogen) for 24 hours, 72 hours, or 7 days.
The collection of blood samples was approved by the Ethics Committee of the University of Lübeck, and informed consent was obtained according to the Declaration of Helsinki.
LDH cytotoxicity assay
Cytotoxicity of 17-DMAG was measured by a lactate dehydrogenase (LDH)-releasing assay using a Cytotoxicity Detection Kit (Roche) according to the manufacturer’s protocol and quantified using an ELISA plate reader. Briefly, PBMCs (1 × 106 per ml) were incubated with 17-DMAG at different concentrations (0.1, 1, and 2.5 μM) for 24 hours. Cell lysis was determined by measuring the amount of LDH released into the culture medium.
A total of 0.5 × 105 PBMCs were cultured in the presence of plate-bound anti-CD3 mAb in 96-well plates. Stimulated cells were cultured alone or with different concentrations of 17-DMAG (0.1, 1, or 2.5 μM). After 6 days, cells were pulsed with BrdU for further 24 hours. T cell proliferation was measured using a colorimetric cell proliferation BrdU ELISA (Roche).
Flow cytometric immunophenotyping
For analysis of intracellular cytokines, PBMCs were stimulated with anti-CD3 mAb without or with 17-DMAG (0.1 μM) for 72 h hours. A GolgiStop™ Protein Transport Inhibitor (BD Pharmingen™) was added together with phorbol-12-myristate-13-acetate (PMA) (50 ng/ml) and ionomycin (1 μg/ml) (Sigma) for the last 5 hours. Cells were washed, fixed, permeabilized, and stained for detection of intracellular cytokines using the following anti-human mAbs: anti-IFN-γ-FITC, anti-IL-17-PE, and anti-CD4-PERCP-CY5.5 (BD Pharmingen). Samples were analyzed using FACSCalibur flow cytometer (BD).
Supernatants of PBMC cultures were collected after a 72-hour treatment period with anti-CD3 mAb in absence or presence of 17-DMAG (0.1 μM). Supernatants were taken from cultures non-treated by GolgiStop, PMA, or ionomycin. Twelve cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IFN-γ, TNF-α, G-CSF, and TGF-β1) were measured by a Human Th1/Th2/Th17 Cytokines Multi-Analyte ELISArray Kit (Qiagen Biosciences).
Determination of NFκB p65 activity
For analysis of NFκB p65 activity, PBMCs were stimulated with anti-CD3 mAb without or with different concentrations of 17-DMAG (0.1, 1, and 2.5 μM) for 24 hours. NFκB p65 activity was measured in cell lysates by a NFκB p65 ELISA kit following the manufacturer’s instruction (Enzo).
Equal amounts of PBMC lysates were separated by 10% SDS-PAGE gel and transferred onto nitrocellulose membrane. The membrane was blocked with 3% milk in PBS for 2 hours, followed by incubation with rabbit polyclonal antibodies against NFκB p65 (1:1000; Santa Cruz Biotechnology, Inc.), Hsp70 (1:100; Stressgen), p-Lck (Tyr394) (1:1000; Sigma), and β-actin (1:1000; Cell Signaling Technology) at room temperature for 2 hours. Horseradish peroxidase-conjugated gout anti-rabbit antibodies (1:1000; Dako) were used as secondary antibodies. The bands were visualized using Amersham ECL Plus Western Blotting Detection Reagents (GE Healthcare). Relative NFκB p65, Hsp70, and p-Lck (Tyr394) protein concentrations were measured by densitometry.
Data was analyzed by Student’s t-test or one-way analysis of variance (ANOVA) using Graphpad prism 5 (San Diego, California). A P-value <0.05 was considered to indicate a statistically significant difference.
17-DMAG arrests proliferation of T cells
17-DMAG inhibits proinflammatory Th1 and Th17 cell subpopulations
17-DMAG dampens the secretion of proinflammatory cytokines
17-DMAG suppresses NFκB p65 activity
17-DMAG upregulates Hsp70 expression
17-DMAG blocks Lck phosphorylation
Here, we provide evidence that 17-DMAG, upon non-toxic concentrations, inhibited T cell proliferation and reduced percentages of Th1 and Th17 cells, which was associated with dampened Th1 (IFN-γ and TNF-α) and Th17 (IL-17) cytokine secretion. These results are in good agreement with previous studies reporting the capacity of Hsp90 blockers to inhibit proliferation of T lymphocytes ex vivo and to downregulate these proinflammatory T cell subtypes[4–11, 13].
Since Th1 and Th17 cells are essential to the development of various autoimmune diseases, treatment strategies which aim at blocking of uncontrolled activation of such effector cell populations are highly warranted. In fact, pharmacological blockade of Hsp90 has been reported to be an effective treatment in rodent models of T cell-mediated autoimmune diseases, such as autoimmune encephalomyelitis, rheumatoid arthritis[7, 8], and systemic lupus erythematosus[9, 10]. In addition, our research group recently demonstrated that, by downregulating T cell responses, treatment with Hsp90 inhibitors is also effective in mice with the experimentally induced autoimmune bullous disease epidermolysis bullosa acquisita.
Although the main focus of our experiments was to study the impact of 17-DMAG on Th1 and Th17 subpopulations, we cannot rule out but also not support that 17-DMAG additionally exhibited suppressive activity on other T cell populations such as Th2 and regulatory T cells since Th2 cytokines released from anti-CD3 antibody-stimulated PBMCs were below the detection limit of our assay and secreted IL-10 and TGF-β1, cytokines associated with regulatory T cell function, were also undetectable or not significantly inhibited in our study, respectively. In this context, it is worth noting that there is evidence in the recent literature that Hsp90 inhibition can promote rather than inhibit regulatory T cells, further supporting an antiinflammatory mechanism of action of Hsp90 blockers in terms of T cell responses[14, 15].
Our current experiments further revealed that inhibition of T cells by 17-DMAG was associated with deactivation of NFκB and upregulation of Hsp70. While NFκB is a client of Hsp90 and one of the major transcription factors responsible for proliferation of T cells and their proinflammatory IFN-γ and IL-17 expression[16, 17], Hsp70 is generally considered as a marker for effective Hsp90 inhibition and also regarded as potent antiinflammatory chaperone capable of inhibiting NFκB signaling pathways[18–20].
Corticosteroids, which are widely used to treat patients with autoimmune diseases, mediate their immunosuppressive effects through cytosolic ligand-inducible glucocorticoid receptors. Inactive glucocorticoid receptors are associated with (co)chaperones, including Hsp90, which dissociate after their ligation, followed by nuclear translocation of these receptors and regulation of gene transcription. The glucocorticoid receptor has been described as part of a T cell receptor-linked multiprotein complex containing Hsp90 and the nonreceptor tyrosin kinases Lck and Fyn, which is essential for T cell receptor-dependent Lck/Fyn activation. It has been previously shown that either treatment with dexamethasone or knocking down Hsp90 by Hsp90siRNA induces dissociation of this protein complex, resulting in abrogated T cell receptor signaling as a consequence of impaired Lck/Fyn activation. Similar to this and other previous studies[4, 13, 22], we could show in the current experiments that pharmacological blockade of Hsp90 was associated with inhibition of Lck activation in anti-CD3 antibody-stimulated PBMCs, a mechanism that could further account for the observed immunosuppressive effects of this treatment on T cells.
Considering that inhibition of both NF-kB function and proximal T cell receptor signaling by corticosteroids can be mimicked using Hsp90 inhibitors and that a novel generation of Hsp90 blockers with good tolerability has been reported in the field of cancer treatment[4, 13, 22–25], it remains to be clarified in the future whether this class of drugs can potentially represent an effective alternative for corticosteroid therapy with a better side effect profile in patients with autoimmune diseases.
Together, our results further support the potential use of Hsp90 inhibitors in patients with autoimmune diseases where inappropriate activation of proinflammatory Th1 and Th17 subpopulations frequently occurs.
This work was supported by Deutsche Forschungsgemeinschaft (DFG) Excellence Cluster “Inflammation at Interfaces” (EXC 306/2), DFG KA 3438/1-1, Medical Faculty of the University of Lübeck (E22-2013), and Focus Program “Autoimmunity” at the University of Lübeck.
- Taipale M, Jarosz DF, Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010, 11: 515-528. 10.1038/nrm2918.PubMedView Article
- Srivastava P: Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002, 2: 185-194. 10.1038/nri749.PubMedView Article
- Ulivieri C, Baldari CT: T-cell-based immunotherapy of autoimmune diseases. Expert Rev Vaccines. 2013, 12: 297-310. 10.1586/erv.12.146.PubMedView Article
- Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC: Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013, 190: 1360-1371. 10.4049/jimmunol.1200593.PubMedView Article
- Wang C, Wu L, Bulek K, Martin BN, Zepp JA, Kang Z, Liu C, Herjan T, Misra S, Carman JA, Gao J, Dongre A, Han S, Bunting KD, Ko JS, Xiao H, Kuchroo VK, Ouyang W, Li X: The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol. 2013, 14: 72-81.PubMedPubMed CentralView Article
- Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL: The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem. 2006, 99: 1351-1362. 10.1111/j.1471-4159.2006.04221.x.PubMedView Article
- Rice JW, Veal JM, Fadden RP, Barabasz AF, Partridge JM, Barta TE, Dubois LG, Huang KH, Mabbett SR, Silinski MA, Steed PM, Hall SE: Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58: 3765-3775. 10.1002/art.24047.PubMedView Article
- Yun TJ, Harning EK, Giza K, Rabah D, Li P, Arndt JW, Luchetti D, Biamonte MA, Shi J, Lundgren K, Manning A, Kehry MR: EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol. 2011, 186: 563-575. 10.4049/jimmunol.1000222.PubMedView Article
- Han JM, Kwon NH, Lee JY, Jeong SJ, Jung HJ, Kim HR, Li Z, Kim S: Identification of gp96 as a novel target for treatment of autoimmune disease in mice. PLoS One. 2010, 5: e9792-10.1371/journal.pone.0009792.PubMedPubMed CentralView Article
- Shimp SK, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CM: Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2012, 9: 255-266. 10.1038/cmi.2012.5.PubMedPubMed CentralView Article
- Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM, Somlai C, Westermann J, Schmidt E, Zillikens D, Ludwig RJ, Orosz A: Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood. 2011, 117: 6135-6142. 10.1182/blood-2010-10-314609.PubMedView Article
- Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski P, Ludwig RJ, Zillikens D, Schmidt E, Fischer TW, Kasperkiewicz M: Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. PLoS One. 2013, 8: e70496-10.1371/journal.pone.0070496.PubMedPubMed CentralView Article
- Yorgin PD, Hartson SD, Fellah AM, Scroggins BT, Huang W, Katsanis E, Couchman JM, Matts RL, Whitesell L: Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases. J Immunol. 2000, 164: 2915-2923.PubMedView Article
- De Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H, Bradner JE, Mazitschek R, Kozikowski AP, Matthias P, Hancock WW: Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011, 31: 2066-2078. 10.1128/MCB.05155-11.PubMedPubMed CentralView Article
- Collins CB, Aherne CM, Yeckes A, Pound K, Eltzschig HK, Jedlicka P, De Zoeten EF: Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol. 2013, 6: 960-971. 10.1038/mi.2012.134.PubMedPubMed CentralView Article
- Salminen A, Paimela T, Suuronen T, Kaarniranta K: Innate immunity meets with cellular stress at the IKK complex: regulation of the IKK complex by HSP70 and HSP90. Immunol Lett. 2008, 117: 9-15. 10.1016/j.imlet.2007.12.017.PubMedView Article
- Oh H, Ghosh S: NF-κB: roles and regulation in different CD4(+) T-cell subsets. Immunol Rev. 2013, 252: 41-51. 10.1111/imr.12033.PubMedPubMed CentralView Article
- Dakappagari N, Neely L, Tangri S, Lundgren K, Hipolito L, Estrellado A, Burrows F, Zhang H: An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers. 2010, 5: 31-38.View Article
- Stocki P, Dickinson AM: The immunosuppressive activity of heat shock protein 70. Autoimmune Dis. 2012, 2012: 617213-PubMedPubMed Central
- De Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ: Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects. Cell Stress Chaperones. 2009, 14: 117-131. 10.1007/s12192-008-0066-9.PubMedPubMed CentralView Article
- Pratt WB, Galigniana MD, Morishima Y, Murphy PJ: Role of molecular chaperones in steroid receptor action. Essays Biochem. 2004, 40: 41-58.PubMedView Article
- Löwenberg M, Verhaar AP, Bilderbeek J, Marle J, Buttgereit F, Peppelenbosch MP, Van Deventer SJ, Hommes DW: Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep. 2006, 7: 1023-1029. 10.1038/sj.embor.7400775.PubMedPubMed CentralView Article
- Celec P: Nuclear factor kappa B–molecular biomedicine: the next generation. Biomed Pharmacother. 2004, 58: 365-371. 10.1016/j.biopha.2003.12.015.PubMedView Article
- Orosz A, Szabo A, Szeman G, Janaky T, Somlai C, Penke B, Bodor A, Perczel A: Novel nontoxic heat shock protein 90 inhibitors having selective antiproliferative effect. Int J Biochem Cell Biol. 2006, 38: 1352-1362. 10.1016/j.biocel.2006.01.015.PubMedView Article
- Garcia-Carbonero R, Carnero A, Paz-Ares L: Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013, 14: e358-e369. 10.1016/S1470-2045(13)70169-4.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.